Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ruxolitinib cream in non-segmental vitiligo
NL-OMON49311Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Ruxolitinib cream 1.5% BID with Vehicle BID (2 arms). Primary endpoint: Proportion achieving F-VASI75 at Week 24. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NL-OMON49311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49311.